TFPI

TFPI Molekülinformation

Englischer Name	Tissue factor pathway inhibitor	Anzahl der inverkehr gebrachten Arzneimittel	2
Anzahl der klinischen Arzneimittel	3	Target-Alias	TFPI，Tissue Factor Pathway Inhibitor，Extrinsic Pathway Inhibitor，TFPI1，LACI，EPI，Anti-Convertin，TFI，Lipoprotein-associated coagulation inhibitor，Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Tissue factor pathway inhibitor
Target-Alias	TFPI，Tissue Factor Pathway Inhibitor，Extrinsic Pathway Inhibitor，TFPI1，LACI，EPI，Anti-Convertin，TFI，Lipoprotein-associated coagulation inhibitor，Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
Anzahl der inverkehr gebrachten Arzneimittel	2
Anzahl der klinischen Arzneimittel	3
Höchste Forschungs- und Entwicklungsphase	Approved

TFPI Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
TFI-H5226	Human	HEK293	Human TFPI Protein, His Tag (active enzyme)				In den Warenkorb legen

Gesamtmenge1

TFPI Molekülhintergrund

Tissue factor pathway inhibitor (TFPI) is also known as Extrinsic pathway inhibitor (EPI), Lipoprotein - associated coagulation inhibitor (LACI), is a plasma proteinase inhibitor synthesized by vascular endothelial cells and part of it is associated with glycosaminoglycans of these cells. TFPI is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa) and Thrombin (Factor IIa). TFPI is a secreted protein with a Nterminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a Cterminal basic region. The first K domain inhibits coagulation factor VIIa complexed to tissue factor (TF); The second K domain inhibits factor Xa; The third K domain binds to heparin; The Cterminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces.

TFPI Molekülalias

TFPI,LACI,TFPI1,EPI,TFI

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
KN-057	KN-057; KN057	Phase 3 Clinical	Suzhou Alphamab Co Ltd	Hemophilia A; Hemophilia B	Details
MG-1113	MG-1113; MG-1113A	Phase 1 Clinical	GC Biopharma Corp	Hemophilia A	Details
AP-017	AP017; AP-017	Phase 1 Clinical	Anyuan Pharmaceutical Technology (Shanghai) Co Ltd	Hemophilia A; Hemophilia B	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Concizumab	Anti-TFPI; mAb-2021; NNC-0172-2021; NNC-172-2021; mAbTFPI2021; NN-7415; NNC-0172-0000-2021	Approved	Novo Nordisk A/S	Alhemo	Canada	Hemophilia B	Novo Nordisk Canada Inc	2023-04-17	Hemophilia A; Hemophilia B; Hemorrhage	Details
Marstacimab	PF-6741086; PF-06741086	Approved	Pfizer Inc	HYMPAVZI, 友瑞宁	United States	Hemophilia A; Hemophilia B	Pfizer Inc	2024-10-11	Hemophilia A; Hemophilia B; Hemorrhage	Details